1. Market Research
  2. > Healthcare
  3. > Managed Care Market Trends

Global Public Health Partnering 2010-2017: Deal trends, players and financials

  • March 2017
  • 1000 pages
  • Currentpartnering
Report ID: 3021539

Summary

Table of Contents

Summary
Global Public Health Partnering 2010-2017: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the public health partnering deals and agreements entered into by the worlds leading healthcare companies

Description
Global Public Health Partnering 2010 to 2017 provides the full collection of Public Health disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Public Health partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Public Health partnering agreement structure
Public Health partnering contract documents
Top Public Health deals by value
Most active Public Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.

The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Public Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Public Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Public Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Public Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2010. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.

Report scope
Global Public Health Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.

Global Public Health Partnering 2010 to 2017 includes:
- Trends in Public Health dealmaking in the biopharma industry since 2010
- Analysis of Public Health deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Public Health deal contract documents
- Comprehensive access to over 3500 Public Health deal records
- The leading Public Health deals by value since 2010
- Most active Public Health dealmakers since 2010

The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.

In Global Public Health Partnering 2010 to 2017, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Public Health Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 200 public health deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Global Public Health Partnering 2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of Public Health deal trends since 2010
- Access Public Health deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Public Health partner companies
- Comprehensive access to over 750 links to actual Public Health deals entered into by the world’s biopharma companies
- Indepth review of Public Health deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Public Health opportunities
- Uncover companies actively partnering Public Health opportunities

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Public Health Partnering 2010 - 2017: Deal trends, players and financials

  • $ 2995
  • Industry report
  • April 2017
  • by Currentpartnering

Global Public Health Partnering 2010-2017: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the public health partnering deals and agreements entered ...

HMO Providers - Industry Market Research Report

  • $ 1090
  • Industry report
  • May 2017
  • by Ibisworld

In remission: Rising aggregate health expenditure will foster demand for HMO-provided coverage HMO Providers Despite decreasing penetration of the employer and Medicare markets, the HMO Providers industry ...

2017 U.S. HMO Medical Centers Industry-Industry & Market Report

  • $ 149
  • Industry report
  • April 2017
  • by Barnes Reports

The U.S. HMO Medical Centers Industry-Industry & Market Report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2017 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.